Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Next Generation of Antidiabetic Drugs Discussed: Tokyo Seminar
September 15, 2008
- Suzuken Expects Price Settlement Rate of Over 70% at the End of September
September 15, 2008
- No Subjective Symptoms in 27% of Glaucoma Patients with Impairment of Half of Visual Field
September 15, 2008
- World's 1st Drug for Idiopathic Pulmonary Fibrosis Recommended for Approval
September 15, 2008
- Shionogi to Enter US Market by Acquiring Sciele
September 15, 2008
- DSP to Design Independent US Marketing System by Mid-2009
September 15, 2008
- Kowa to Start Independent Marketing of Livalo in the US in 2010
September 15, 2008
- PMDA Considers New System to Ensure Greater Post-Marketing Safety
September 15, 2008
- Otsuka to Codevelop Drug for Dry AMD with Acucela
September 15, 2008
- NICE to Recommend Lucentis to Treat Wet AMD under Health Insurance
September 15, 2008
- VEGF Trap-Eye Improves Vision in Patients with AMD: Bayer, Regeneron
September 15, 2008
- Recommending Hp Eradication in All Infected Persons: JSHR
September 8, 2008
- Takara Bio to Start Cancer Cell Immunotherapy in Kyoto Clinic
September 8, 2008
- Takeda Suspends Development of Hematide for Chemotherapy-Induced Cancerous Anemia
September 8, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 8, 2008
- CGI to Stop PIII Trial on Prostate Cancer Vaccine Licensed to Takeda
September 8, 2008
- METI Demands \609.3 Bil. to Promote Science & Technology
September 8, 2008
- PM Yasuo Fukuda Steps Down
September 8, 2008
- Korosho to Demand \33.2 Bil. to Develop Drugs, Med. Devices
September 8, 2008
- Committee Recommends Approval of Generic Vancomycin from Mylan
September 8, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…